PL2056675T3 - Metody leczenia zapalenia błony śluzowej jamy ustnej - Google Patents

Metody leczenia zapalenia błony śluzowej jamy ustnej

Info

Publication number
PL2056675T3
PL2056675T3 PL07839531T PL07839531T PL2056675T3 PL 2056675 T3 PL2056675 T3 PL 2056675T3 PL 07839531 T PL07839531 T PL 07839531T PL 07839531 T PL07839531 T PL 07839531T PL 2056675 T3 PL2056675 T3 PL 2056675T3
Authority
PL
Poland
Prior art keywords
methods
oral mucositis
treating oral
treating
mucositis
Prior art date
Application number
PL07839531T
Other languages
English (en)
Inventor
David M. Rothstein
Chris Murphy
Vivian Wong
Glen Kazo
Original Assignee
Galera Labs, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs, Llc filed Critical Galera Labs, Llc
Publication of PL2056675T3 publication Critical patent/PL2056675T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL07839531T 2006-10-12 2007-10-12 Metody leczenia zapalenia błony śluzowej jamy ustnej PL2056675T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82929106P 2006-10-12 2006-10-12
EP07839531.6A EP2056675B1 (en) 2006-10-12 2007-10-12 Methods of treating oral mucositis
US11/871,848 US9855279B2 (en) 2006-10-12 2007-10-12 Methods of treating oral mucositis
PCT/US2007/021897 WO2008045559A2 (en) 2006-10-12 2007-10-12 Methods of treating oral mucositis

Publications (1)

Publication Number Publication Date
PL2056675T3 true PL2056675T3 (pl) 2019-08-30

Family

ID=39283481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07839531T PL2056675T3 (pl) 2006-10-12 2007-10-12 Metody leczenia zapalenia błony śluzowej jamy ustnej

Country Status (13)

Country Link
US (5) US9855279B2 (pl)
EP (2) EP2056675B1 (pl)
AU (1) AU2007308141B2 (pl)
CA (1) CA2665984C (pl)
CY (1) CY1121530T1 (pl)
DK (1) DK2056675T3 (pl)
ES (1) ES2725023T3 (pl)
HU (1) HUE044234T2 (pl)
LT (1) LT2056675T (pl)
PL (1) PL2056675T3 (pl)
PT (1) PT2056675T (pl)
SI (1) SI2056675T1 (pl)
WO (1) WO2008045559A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2665984C (en) 2006-10-12 2017-02-28 Activbiotics, Inc. Superoxide dismutase mimetics for the treatment of oral mucositis
US9198893B2 (en) * 2008-05-22 2015-12-01 Galera Labs, Llc Combination antitumor therapy
SI3284459T1 (sl) 2011-04-29 2021-07-30 Moberg Pharma Ab Farmacevtski sestavki, ki vsebujejo lokalni anestetik kot na primer bupivacain za lokalno dajanje v usta ali grlo
US9149483B2 (en) * 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
DE102012013482A1 (de) * 2012-07-09 2014-01-09 Bitop Ag Zusammensetzung zur Förderung der Wiederherstellung von verletztem Körpergewebe
WO2017027728A1 (en) 2015-08-11 2017-02-16 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
CN109906081A (zh) * 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
SG11202007317XA (en) * 2018-01-31 2020-08-28 Galera Labs Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2020036975A1 (en) * 2018-08-14 2020-02-20 Tosk, Inc. Methods and compositions for reducing fluorouracil induced toxicity
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2023009500A1 (en) * 2021-07-27 2023-02-02 Galera Labs, Llc Pentaaza macrocyclic ring complex for enhanced surgical treatment
WO2023224135A1 (ko) * 2022-05-16 2023-11-23 주식회사 제노포커스 수퍼옥시드 디스뮤타제 및 이의 점막염 예방 또는 치료용 용도
WO2024026273A1 (en) * 2022-07-25 2024-02-01 Galera Labs, Llc Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) * 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) * 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) * 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) * 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2072934C (en) * 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0598753B1 (en) 1991-07-19 1998-03-18 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1152880A (zh) 1994-04-22 1997-06-25 孟山都公司 使用含氮大环配拉体的金属络合物的诊断图像分析的方法
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) * 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
JPH11511168A (ja) 1995-08-17 1999-09-28 モンサント カンパニー 窒素含有大環状リガンドの金属錯体の生体分子結合体を使用する診断造影検査方法
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
ATE383364T1 (de) 1999-05-27 2008-01-15 Monsanto Co Biomaterialien, modifiziert mit superoxid- dismutase imitatoren
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
CA2399293C (en) 2000-02-08 2012-01-03 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
AU2000265525A1 (en) 2000-08-29 2002-03-13 Mepha Ag Medicament for treating intestinal diseases
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
AU2002241807A1 (en) 2001-01-05 2002-07-16 Metaphore Pharmaceuticals, Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
US20030050297A1 (en) * 2001-01-19 2003-03-13 Crapo James D. Cancer therapy
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
RU2003129271A (ru) 2001-03-02 2005-03-20 Метафор Фармасьютикалз, Инк. (Us) Хроматография комплексов металлов
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002100395A1 (en) * 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
HU230378B1 (hu) 2001-11-01 2016-03-29 Uab Research Foundation Anti-DR5 ellenanyagok és anti-DR4 ellenanyagok és más terápiás ágensek kombinációi
EP1501526A1 (en) * 2002-04-16 2005-02-02 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
WO2005097123A2 (en) 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-substituted porphyrin compounds and methods of use thereof
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20090099150A1 (en) 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
TWI316937B (en) * 2005-03-31 2009-11-11 Schering Corp Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电***传声器扣合式封装结构
US20100158857A1 (en) 2006-05-23 2010-06-24 University Of Utah Research Foundation Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
CA2665984C (en) 2006-10-12 2017-02-28 Activbiotics, Inc. Superoxide dismutase mimetics for the treatment of oral mucositis
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
US20090221622A1 (en) 2008-02-29 2009-09-03 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
US20090257979A1 (en) 2008-04-15 2009-10-15 Intermune, Inc. Novel Inhibitors of Hepatitis C Virus Replication
US9198893B2 (en) 2008-05-22 2015-12-01 Galera Labs, Llc Combination antitumor therapy
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
US9149483B2 (en) 2011-09-26 2015-10-06 Galera Labs, Llc Methods for treatment of diseases
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
WO2017027728A1 (en) 2015-08-11 2017-02-16 Galera Labs, Llc Pentaaza macrocyclic ring complexes possessing oral bioavailability
SG10202106462TA (en) 2016-05-03 2021-07-29 Galera Labs Llc Combination therapy for cancer treatment
CN109906081A (zh) 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
CA3053779A1 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
CA3059581A1 (en) 2017-04-13 2018-10-18 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
SG11202007317XA (en) 2018-01-31 2020-08-28 Galera Labs Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Also Published As

Publication number Publication date
DK2056675T3 (en) 2019-04-23
US10610533B2 (en) 2020-04-07
AU2007308141B2 (en) 2013-08-29
WO2008045559A3 (en) 2008-07-31
HUE044234T2 (hu) 2019-10-28
US11612608B2 (en) 2023-03-28
PT2056675T (pt) 2019-05-09
US9855279B2 (en) 2018-01-02
AU2007308141A1 (en) 2008-04-17
CY1121530T1 (el) 2020-05-29
US20180333421A1 (en) 2018-11-22
EP2056675A4 (en) 2011-01-19
CA2665984A1 (en) 2008-04-17
EP3527079A1 (en) 2019-08-21
EP2056675B1 (en) 2019-01-09
EP2056675A2 (en) 2009-05-13
US20230218633A1 (en) 2023-07-13
LT2056675T (lt) 2019-05-27
US20080269185A1 (en) 2008-10-30
SI2056675T1 (sl) 2019-08-30
US20200215077A1 (en) 2020-07-09
US9642861B2 (en) 2017-05-09
WO2008045559A2 (en) 2008-04-17
CA2665984C (en) 2017-02-28
ES2725023T3 (es) 2019-09-18
US20140343028A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
PL2056675T3 (pl) Metody leczenia zapalenia błony śluzowej jamy ustnej
IL248204A0 (en) Combined treatment of tumors expressing 38cd
ZA200900388B (en) Compositions and methods for the treatment of mucositis
EP2032131A4 (en) Methods of Treatment
IL198663A0 (en) Tissue treatment methods
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
IL193460A0 (en) Compounds and methods for treatment of stroke
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
GB0610746D0 (en) Method of treatment
EP2034830A4 (en) PROCESS FOR TREATMENT OF STROKE
EP1855729A4 (en) sterilization
GB0600692D0 (en) Well treatment
ZA200900140B (en) Methods and compositions for treating biofilms
GB0608190D0 (en) Method of purification
GB0705854D0 (en) Methods of construction
HK1129596A1 (en) Methods and compositions for treating disease
ZA200900638B (en) Method of diagnosis
EP2164494A4 (en) Methods of Treatment
ZA200900896B (en) Aza-benzofuranyl compounds and methods of use
GB0618060D0 (en) Treatment of polyamides
IL194798A0 (en) Treatment of melanoma
ZA200900639B (en) Method of diagnosis
GB0623740D0 (en) Treatment of disease
ZA200901009B (en) Aza-benzothiophenyl compounds and methods of use